PDX Models

Patient-Derived Tumor Xenograft Model (PDX): This model is established by directly transplanting the patient's tumor tissue into immunodeficient mice. The characteristics of most primary tumors in histopathology, molecular biology and gene level, ensuring relatively reliable predictions of clinical efficacy. Therefore, the platform is widely used in the development of new drugs, especially in the selection of patients in clinical trials of target drugs and the study of predictive biomarkers.

Download

Model Type

Patient-Derived Tumor Xenograft (PDX) model retains the characteristics of patients’ tumor tissues and features more clinical relevance. Combined with humanized mice, the model can promise ideal evaluation of tumor immuno-oncology. Now, we have the following models:

Cancer Type	Cell Lines
Colon cancer	PDXM-008C, PDXM-016C, PDXM-020C, PDXM-021C, PDXM-057C, PDXM-060C, PDXM-075C, PDXM-076C, PDXM-087C, PDXM-104C, PDXM-095C, PDXM-084C, PDXM-072C, PDXM-069C, PDXM-057C, PDXM-015C, PDXM-002C,
Lung cancer	PDXM-054Lu, PDXM-050Lu, PDXM-047Lu, PDXM-053Lu, PDXM-028Lu,
Gastric cancer	PDXM-092Ga, PDXM-091Ga,
Breast cancer	PDXM-201B
Liver cancer	PDXM-211Li
Pancreas cancer	PDXM-221Pa, PDXM-222Pa

PDX Models
SNI:Neuro-Oncology 2015, Vol 6, Suppl I - A supplement to Surgical Neurology International

Our research on PDX model includes molecular level genotyping and pharmacological efficacy evaluation service of orthotopic model, promising great prediction for clinical efficacy research.